Online inquiry

IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15758MR)

This product GTTS-WQ15758MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Renal cell carcinoma (RCC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15758MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1067MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ7110MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FE 999301
GTTS-WQ5485MR IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP 6038
GTTS-WQ15855MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb5871
GTTS-WQ11641MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ4367MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ7606MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF-Fc-PEG(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA G-CSF-Fc-PEG
GTTS-WQ7054MR IVTScrip™ mRNA-Anti-VEGFA, Fab-12 variant Y0317(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Fab-12 variant Y0317
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW